Summary

Overview
Global Stone Disease Market reached US$ XX billion in 2022 and is expected to reach US$ XX million by 2030 growing at a CAGR of XX% during the forecast period 2023-2030.
Stone disease or urolithiasis are hard deposits made of minerals and salts that form inside the kidneys. It is characterized by stone production in the kidney, bladder, and urinary tract. Stone formation in the locations mentioned above is mostly caused by decreased urine volume and increased excretion of stone-forming chemicals such as oxalate, calcium, cysteine, urate, phosphate, and xanthine.
Kidney stones can be effectively treated due to the availability of modern procedures, accompanying medical technologies, and kidney stone management devices. Stone disease is widely treated by medical procedures namely shockwave lithotripsy, ureteroscopy, and percutaneous nephrolithotomy.
Market Dynamics
Increasing prevalence of kidney stones
The increasing product launches act as a significant driver for market growth. Kidney stones are hard deposits of minerals and acid salts that stick together in concentrated urine. Eating a diet that is high in protein, sodium and sugar can increase the risk of some types of kidney stones.
For instance, according to the Kidney Foundation of Canada, kidney stones are common in Canada and appear to be on the rise over the last 25 years. About 12% of men and 6% of women will have a kidney stone at some point in their life. In men, the first kidney stone is usually diagnosed between the ages of 40 and 60.
Also, according to the International Journal of Molecular Medicine published in 2021, the prevalence of kidney stones was 5.8% among Chinese adults (6.5% in men and 5.1% in women), with about 1 in 17 adults currently affected.
Furthermore, significant growth drivers such as rising demand for minimally invasive procedures, and advancements in ureteroscopy techniques are expected to drive the market in the forecast period.
Side effects related to percutaneous nephrolithotomy
Despite the increasing incidence of stone diseases, certain factors limit the adoption of its treatment. One of the major factors obstructing the market's growth is its side effects, such as bleeding around the kidneys, blockage of urine due to broken stones, infections, and an increase in arterial blood pressure, among others. These complications are expected to hinder the market growth during the forecast period.
Segment Analysis
The global stone disease market is segmented based on type, treatment, sales channel and region.
The shockwave lithotripsy segment accounted for approximately 49.1% of the market share
The shockwave lithotripsy segment is expected to hold the largest market share over the period forecast. Lithotripsy treats kidney stones by sending focused ultrasonic energy or shock waves directly to the stone first located with fluoroscopy or ultrasound. The shock waves break a large stone into smaller stones that will pass through the urinary system.
According to the Research Square Article, 2021, calcium stones were the most common in all countries (up to 91%), with Canada and China having the highest incidence. Except in Egypt and India, oxalate stones were more common than phosphate or mixed phosphate/oxalate stones. Uric acid stones are more common in Egypt, India, Pakistan, Iraq, Poland, and Bulgaria.
For instance, in February 2021, Shockwave Medical, Inc. received Pre-Market Approval for severely calcified coronary artery disease from the U.S. FDA. The innovative technology, which was granted Breakthrough Device designation by the FDA, is a novel application of lithotripsy, an approach that has been used for decades to safely break up kidney stones. Hence, due to the above factors, the segment is expected to hold the largest market share.
Geographical Analysis
North America is expected to hold a significant position in the global stone disease market share
North America has maintained a significant market proportion due to factors such as the rising prevalence of nephrolithiasis, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.
For instance, according to the National Institute of Health Report 2023, the prevalence and recurrence rates of nephrolithiasis are increasing, with limited options of effective drugs and procedures, affecting about 12% of the population worldwide. The incidence is estimated at 600,000 in the U.S. Between the ages of 20 to 49.
Additionally, in the United States, kidney stones send more than 500,000 people to the emergency room each year, as stated by the National Kidney Foundation. As per the statistics, the increasing patient pool and disposable revenue in this country boost the region's market growth.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the global stone disease market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatment, product launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the stone disease market is expected to be moderately affected over the forecast period.
Market Segmentation
By Type
• Calcium oxalate
• Uric acid
• Struvite
• Cystine
By Treatment
• Medications
o Alpha Blockers
 tamsulosin
 alfuzosin
 silodosin
 naftopidil
o Thiazide Diuretics
 Hydrochlorothiazide
 Chlorthalidone
 Indapamide
o Allopurinol
• Surgery
o Shockwave Lithotripsy (SWL)
o Ureteroscopy
o Percutaneous Nephrolithotomy (PCNL)
• Device
o Lithotripters
o Ureteral Stents
o Ureterorenoscope
By Sales Channel
• Distribution Channel
o Hospital Pharmacy
o Retail Pharmacy
o Online Pharmacy
• End User
o Hospitals
o Ambulatory Surgical Centers
o Specialty Clinics
o Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Boston Scientific Corporation, Becton Dickinson and Company, Cook Medical Inc., Olympus Corporation, Storz Medical AG, Richard Wolf GmbH, Dornier MedTech GmbH, DirexGroup, Stryker Corporation, Zhuhai Shixin Medical Technology Co.Ltd among others.
Key Developments
• In February 2023, Boston Scientific received FDA Clearance for LithoVue Elite Single-Use Digital Flexible Ureteroscope System. It is designed to inform real-time clinical decisions during kidney stone procedures.
• In July 2022, Calyxo raised $32.7M for the CVAC Aspiration system designed to use irrigation and aspiration to remove kidney stones with the goal of a surgically stone-free outcome.
Why Purchase the Report?
• To visualize the global stone disease market segmentation based on type, treatment, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global stone disease market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global stone disease market report would provide approximately 61 tables, 59 figures, and 185 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by Sales Channel
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of kidney stones
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Side effects related to percutaneous nephrolithotomy
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Calcium oxalate*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Uric acid
7.4. Struvite
7.5. Cystine
8. By Treatment
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Medications*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Alpha Blockers
8.2.3.1. tamsulosin
8.2.3.2. alfuzosin
8.2.3.3. silodosin
8.2.3.4. naftopidil
8.2.4. Thiazide Diuretics
8.2.4.1. Hydrochlorothiazide
8.2.4.2. Chlorthalidone
8.2.4.3. Indapamide
8.2.5. Allopurinol
8.3. Surgery
8.3.1. Shockwave Lithotripsy (SWL)
8.3.2. Ureteroscopy
8.3.3. Percutaneous Nephrolithotomy (PCNL)
8.4. Device
8.4.1. Lithotripters
8.4.2. Ureteral Stents
8.4.3. Ureterorenoscope
9. By Sales Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
9.1.2. Market Attractiveness Index, By Sales Channel
9.2. Distribution Channel*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.2.3. Hospital Pharmacy
9.2.4. Retail Pharmacy
9.2.5. Online Pharmacy
9.3. End User
9.3.1. Hospitals
9.3.2. Ambulatory Surgical Centers
9.3.3. Specialty Clinics
9.3.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Boston Scientific Corporation
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Becton Dickinson and Company
12.3. Cook Medical Inc.
12.4. Olympus Corporation
12.5. Storz Medical AG
12.6. Richard Wolf GmbH
12.7. Dornier MedTech GmbH
12.8. DirexGroup
12.9. Stryker Corporation
12.10. Zhuhai Shixin Medical Technology Co.Ltd
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us